Table 1 Demographic and clinical characteristics of patients undergoing minimally invasive esophagectomy (N = 142)
From: A refined procedure for esophageal resection using a full minimally invasive approach
Characteristic | Â |
|---|---|
Demographics | |
Age at time of surgery [years] | |
 Mean (SD) | 64.5 (9.6) |
 Median (IQR) | 66.5 (59–70) |
Male gender [N (%)] | 121 (85.2%) |
BMI [kg/m2] | |
 Mean (SD) | 27.4 (5.4) |
Race [N (%)] | |
 African-American | 7 (4.9%) |
 Asian | 12 (8.5%) |
 Native American | 1 (0.7%) |
 White | 122 (85.9%) |
Hispanic [N (%)] | 10 (7.0%) |
Clinical characteristics | |
Primary site [N (%)] | |
 Mid-thoracic esophagus | 13 (9.2%) |
 Lower thoracic esophagus | 76 (53.5%) |
 Gastroesophageal junction | 53 (37.3%) |
Histology [N (%)] | |
 Adenocarcinoma | 127 (89.4%) |
 Squamous cell carcinoma | 11 (7.8%) |
 Other | 4 (2.8%) |
Clinical stage [N (%)] | Â |
 Stage 0 | 2 (1.4%) |
 Stage I | 10 (7.0%) |
 Stage IIa | 4 (2.8%) |
 Stage IIb | 9 (6.3%) |
 Stage III | 85 (59.9%) |
 Stage IVA | 32 (22.5%) |
 Stage IVB | 0 (0%) |
Pathologic stage [N (%)] | |
 Stage 0 | 28 (19.7%) |
 Stage I | 22 (15.5%) |
 Stage IIa | 7 (4.9%) |
 Stage IIb | 17 (12.0%) |
 Stage III | 39 (27.5%) |
 Stage IVA | 28 (19.7%) |
 Stage IVB | 1 (0.7%) |
Regional lymph nodes involved (Clinical staging) [N (%)] | 87 (61.3%) |
Regional lymph nodes involved (Pathologic staging) [N (%)] | 53 (37.3%) |
ECOG performance status [N (%)] | |
 0 | 42 (29.6%) |
 1 | 48 (33.8%) |
 2 | 12 (8.5%) |
 Unknown | 40 (28.2%) |
Neoadjuvant therapy [N (%)] | |
 Radiation therapy only | 1 (0.7%) |
 Chemotherapy only | 15 (10.6%) |
 Chemoradiation | 109 (76.8%) |
 None | 17 (12.0%) |
Preoperative ASA Category [N (%)] | |
 1 | 0 (0%) |
 2 | 50 (35.2%) |
 3 | 91 (64.1%) |
 4 | 1 (0.7%) |
 5 | 0 (0%) |
Clinical comorbidities [N (%)] | |
Hypertension | 87 (61.3%) |
Diabetes | 47 (33.1%) |
Coronary artery disease | 43 (30.3%) |
Heart failure | 8 (5.6%) |
Chronic renal insufficiency | 26 (18.3%) |
Chronic obstructive pulmonary disease | 13 (9.2%) |
Stroke/Transient ischemic attack | 4 (2.8%) |
Charlson-Quan Comorbidity Index | |
 Mean (SD) | 6.0 (5.6–6.4) |
 Median (IQR) | 7 (4–8) |